Solorank
Login

Cached score snapshot

US.DXCM · Dexcom

110分制 58.9/110；5D動能v2 3/50；排序分 61.9/160

Back to ranking Open volume snapshot
Ranking score 61.9/160
Main score 58.9/110
5D momentum v2 3/50
Rank #135
Setup grade F 28.6

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 28.6 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 07-01 09-24 10-09 10-23 11-05 $65.02$85.66$106.31 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling calibration best · score 2.515 · anchors 120 +0.43% -1.66% / +2.26% 55% 0% Actual -0.95% · vs median -1.38% · inside 25-75 band
30D observation +7.77% +0.77% / +12.60% 77.5% 2.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.53% -1.78% / +2.59% 58.1% 4.4% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-07-01 → 2026-11-05 · 235 archived points · 4 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 61.9
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 58.9/110 (觀望)
5D momentum v2 3/50 (弱)
Score with momentum v2 61.9/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 87.7105
ma50 84.959
close 87.47
prevClose 87.73
avgVolume20 4062331
volumeRatio 0.52
changePercent -0.3

Metrics snapshot

close 87.47
volume 2124433
changePercent -0.3

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 58.9/110
Main rating 觀望
5D momentum v2 3/50
Score with momentum v2 61.9/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.6/5 · 優秀
Dimension score 4.6/5
Dimension grade 優秀

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0.75
roePoints 0.75
debtPoints 0.5
marginPoints 0.6
turnoverUsdM 185.8242
volumePoints 0.5
revenuePoints 0.6
dividendPoints 0
marketCapPoints 0.5

資金流 — 11.6/20 · 較差
Dimension score 11.6/20
Dimension grade 較差

Sub-items

cmfPoints 1.6
mfiPoints 3.2
obvPoints 4
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.DXCM
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 11/15 · 良好
Dimension score 11/15
Dimension grade 良好

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 14.21

trend

score 4

details

qqq

ma20 719.705
ma50 711.8824
name QQQ
close 741.1
points 2

spy

ma20 765.338
ma50 761.1532
name SPY
close 767.18
points 2
source twelvedata+fred
atrPct 2.7233
atrPoints 3
cciPoints 1.6
vixPoints 2.4
marketTrendPoints 4

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 6.6/10 · 一般
Dimension score 6.6/10
Dimension grade 一般

Sub-items

position

score 1.4

details

atrPct 2.7233
turnoverUsdM 185.8242
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DXCM
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 82.7058

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 5.4
take_profit_price 91.8435
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.4467
diversificationPoints 2

技術信號 — 19.1/30 · 一般
Dimension score 19.1/30
Dimension grade 一般

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 2.4
vcpPoints 1.5
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1.5
vcp_reason 跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N

vcp_metrics

up_days 6
vol_ref 4339169.2333
down_days 3
vcp_ready false
above_ma50 true
avg_vol_10 5003977.7
avg_vol_20 4147238.85
avg_vol_30 4339169.2333
range_pct_10 0.0925
range_pct_20 0.1149
range_pct_30 0.1178
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok true
up_expand_days 3
breakout_20d_ok false
vol_ratio_10_30 1.1532
dist_to_20d_high 0.0527
down_shrink_days 3
breakout_level_20d 92.34
vcp_breakout_confirm false
contraction_ratio_10_30 0.7859
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.8
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 1
volumePointsTechnical 0.4

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":142370918,"url":"https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...","category":"company","datetime":1790224168,"headline":"Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"}, {"id":142366064,"url":"https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...","category":"company","datetime":1790201622,"headline":"DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"}, {"id":142025511,"url":"https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"DXCM","summary":"DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...","category":"company","datetime":1788952625,"headline":"DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"}, {"id":141953963,"url":"https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.","category":"company","datetime":1788871017,"headline":"DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"}, {"id":141425987,"url":"https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...","category":"company","datetime":1788506376,"headline":"DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"}, {"id":141403938,"url":"https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.","category":"company","datetime":1788463638,"headline":"Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"}, {"id":141364461,"url":"https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.","category":"company","datetime":1788275900,"headline":"3 Reasons DXCM Has Explosive Upside Potential"}, {"id":141329259,"url":"https://finnhub.io/api/news?id=30fc1b6357c6f2bc8fc26f712b11c5d05fc571cd1fc2a9682680b6e7df422e18","image":"https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp","source":"ChartMill","related":"DXCM","summary":"Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.","category":"company","datetime":1787829714,"headline":"DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation"}
raw_source {"id":142370918,"url":"https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...","category":"company","datetime":1790224168,"headline":"Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"}, {"id":142366064,"url":"https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...","category":"company","datetime":1790201622,"headline":"DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"}, {"id":142364255,"url":"https://finnhub.io/api/news?id=895685be22cd87859303846feda7f64760fc0297ce940d33c824aa0414d154ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.","category":"company","datetime":1790101500,"headline":"Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring"}, {"id":142310755,"url":"https://finnhub.io/api/news?id=92eed5103bf0ea374a58ca1e7b576333d065b92ab5af27bca906a641b348f8df","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.","category":"company","datetime":1789988065,"headline":"2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down"}, {"id":142307394,"url":"https://finnhub.io/api/news?id=7bc174f162091d9036397952184db2de41e5e61e125e11ffded05e0f7cc529bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- \"Wearable Biosensors Market - Global Forecast to 2036\" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch","category":"company","datetime":1789981440,"headline":"Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players"}, {"id":142271637,"url":"https://finnhub.io/api/news?id=730ce01b8e45e7d0d0cea2dc2e8151ad596a5f7f5e6060130ea168cdd26aa9e1","image":"","source":"Benzinga","related":"DXCM","summary":"Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.","category":"company","datetime":1789735782,"headline":"Truist Securities Maintains Buy on DexCom, Raises Price Target to $102"}, {"id":142271638,"url":"https://finnhub.io/api/news?id=6ee129161211c25318ac879637ad4a449a31809f2b9f29daed78db95040e7dfb","image":"","source":"Benzinga","related":"DXCM","summary":"TD Cowen analyst Joshua Jennings reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.","category":"company","datetime":1789728853,"headline":"TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target"}, {"id":142253117,"url":"https://finnhub.io/api/news?id=e11028fe46d2f48c6ef48e72b060b54606b0ee35c8994be445e30b364af77ec5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.","category":"company","datetime":1789727560,"headline":"2 Unpopular Stocks That Should Get More Attention and 1 We Question"}, {"id":142197315,"url":"https://finnhub.io/api/news?id=f9b690efa346ffbc94d60bb451c6e3888d4bef728ac1204db8a94505ecd775e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.","category":"company","datetime":1789529598,"headline":"Dexcom gives CFO Jereme Sylvain expanded role"}, {"id":142141666,"url":"https://finnhub.io/api/news?id=e1cab6faa1b4651b320e6f31733d8419da2548b0a2da7354abd2eaf3d116e8db","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer","category":"company","datetime":1789417800,"headline":"Dexcom Promotes Jereme Sylvain to Chief Operating Officer"}, {"id":142141667,"url":"https://finnhub.io/api/news?id=c8407fc472f5b8188b750160e88317d29915f29a69289864ca15585955b9537b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.","category":"company","datetime":1789411440,"headline":"Here's Why You Should Retain DexCom Stock in Your Portfolio for Now"}, {"id":142066269,"url":"https://finnhub.io/api/news?id=a9b86a2669b0dee4fa3b7a2d1d65e1fb21112612dcc3ec4f51125f9f2cd786c8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.","category":"company","datetime":1789071300,"headline":"Dexcom Appoints Glenn Boehnlein to Board of Directors"}, {"id":142061722,"url":"https://finnhub.io/api/news?id=1b09565d259ac9bfe618da32adb94625e41d949d1b28c9c53714134c2294b0d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.","category":"company","datetime":1789053664,"headline":"3 Quality Compounders with Impressive Fundamentals"}, {"id":142025511,"url":"https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"DXCM","summary":"DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...","category":"company","datetime":1788952625,"headline":"DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"}, {"id":141953963,"url":"https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.","category":"company","datetime":1788871017,"headline":"DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"}, {"id":141425987,"url":"https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...","category":"company","datetime":1788506376,"headline":"DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"}, {"id":141403938,"url":"https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.","category":"company","datetime":1788463638,"headline":"Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"}, {"id":141396046,"url":"https://finnhub.io/api/news?id=90fc089244dc8485ed1bae6ed814953047aba3ac1c4095ec57995ccba0e89f82","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.","category":"company","datetime":1788414660,"headline":"Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services"}, {"id":141364461,"url":"https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.","category":"company","datetime":1788275900,"headline":"3 Reasons DXCM Has Explosive Upside Potential"}, {"id":141364462,"url":"https://finnhub.io/api/news?id=13c97255d370689eb9f90297a0211b08089b8745c33c05d2de88651317780fa0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.","category":"company","datetime":1788269400,"headline":"Dexcom Announces Upcoming Conference Presentation"}, {"id":141364463,"url":"https://finnhub.io/api/news?id=c9b6fc6bffb3e3d7e0e29642779ed31313c55591b3bc61dab67540e17181933a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.","category":"company","datetime":1788183001,"headline":"Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today"}, {"id":141352563,"url":"https://finnhub.io/api/news?id=62cc47117b3b9089b94543a3b43428caf46231c1d5d9006a1fe7d5275c3d64c8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.","category":"company","datetime":1788100202,"headline":"Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed."}, {"id":141361642,"url":"https://finnhub.io/api/news?id=2d68e10e6a7fe49f93f31c64a7e7e06caaf9f1daf2c0dc4f723072ce37ddb7f2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.","category":"company","datetime":1787861759,"headline":"The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?"}, {"id":141329259,"url":"https://finnhub.io/api/news?id=30fc1b6357c6f2bc8fc26f712b11c5d05fc571cd1fc2a9682680b6e7df422e18","image":"https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp","source":"ChartMill","related":"DXCM","summary":"Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.","category":"company","datetime":1787829714,"headline":"DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation"}, {"id":141361644,"url":"https://finnhub.io/api/news?id=ac13f57821e8edb85d717370a97036cf679147e1084cd7f872b6af7481c57b7b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.","category":"company","datetime":1787828940,"headline":"Dexcom, Abbott await Medicare coverage expansion for CGMs"}, {"id":141323906,"url":"https://finnhub.io/api/news?id=d51cae098bce93cf8ef7e16d66ce95996ebfd0ed923bffa3c37acb05dd0b23af","image":"https://cdn.benzinga.com/files/images/story/2026/08/26/Abbott-Laboratories.jpg?width=2048&height=1536","source":"Benzinga","related":"DXCM","summary":"The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.","category":"company","datetime":1787736992,"headline":"FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking"}, {"id":141364465,"url":"https://finnhub.io/api/news?id=51438755ae79e1fd4c7678dd81bbf96f6a8b8b900a62658aeb72f370bcfe0a48","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.","category":"company","datetime":1787671440,"headline":"Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?"}, {"id":141364468,"url":"https://finnhub.io/api/news?id=f5f23b1f38e5783222ccb643de6fbd02540422cf97dae9f0047cc2cd7a0d4460","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.","category":"company","datetime":1787668380,"headline":"Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?"}, {"id":141364467,"url":"https://finnhub.io/api/news?id=4e934f90b7cbf82177951e0319e55111a0b294d452106cc79bb6226e88699eb9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"We all knew it was coming. The expected valuation may surprise, though.","category":"company","datetime":1787616344,"headline":"Oura is reportedly eyeing a September IPO that could value it at more than $16B"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 29
discarded_article_count 21
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 4.6 5/110 92% 4.6
資金流 11.6 20/110 58% 11.6
市場環境 11 15/110 73.33% 11
催化劑 2 20/110 10% 2
風險管理 6.6 10/110 66% 6.6
技術信號 19.1 30/110 63.67% 19.1
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 3/50
ret_5d -0.0052
max_score 50
max_total 50
raw_total 3
vcp_bonus 0
vol_ratio 0.5123
ret_points 0
vol_points 0
range_ratio 0.481
volat_points 0
day_range_pct 0.0125
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.7233
turnoverUsdM 185.8242
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DXCM
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 82.7058

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 5.4
take_profit_price 91.8435
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.4467
diversificationPoints 2

Calculation audit log

基本面分析總分: 4.6/5分
資金流分析總分: 11.6/20分
市場環境分析總分: 11/15分
催化劑分析: 2/20分
風險管理總分: 6.6/10分
技術信號分析總分: 19.1/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 2.3821
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.72
cci
rule Cursor_18.24 CCI bands
level 弱勢
score 4
value -8.95
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0927
kdj
d 67.89
j 72.19
k 69.32
rule Cursor_18.24 K/D cross
score 6
signal 強金叉
mfi
rule Cursor_18.24 MFI bands
level 入貨中
score 8
value 64.53
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 75475444
recentSlope 2745934.4
previousSlope -1061630
rsi
value 43.36
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 83.2031
position SAR喺價下
distancePct 4.88
previousTrend 上升
ma50
value 84.959
macd
macd 0.6391
trend 中性偏多
signal 0.7491
histogram -0.11
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 87.5867
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 空升
ratio 0.52
score 2
avgVolume 4062331
currentVolume 2124433
derived
ma20 87.7105
ma50 84.959
prevClose 87.73
avgVolume10 4862441
avgVolume20 4062331
changePercent -0.3
avgVolumeForScore 4062331
ma_cross
ma20 87.7105
ma50 84.959
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 87.785
prevMa50 84.6642
spreadPct 3.24
isVolumeBreakout false
bollinger
lower 82.9498
upper 92.4712
position 中間
rsi_short
value 51.41
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.52

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.723333714416371,
        "turnoverUsdM": 185.82415451,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DXCM",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 82.7058,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.4,
      "take_profit_price": 91.8435,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.446667428832742,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 61.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 58.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 87.7105,
    "ma50": 84.959,
    "close": 87.47,
    "prevClose": 87.73,
    "avgVolume20": 4062331,
    "volumeRatio": 0.52,
    "changePercent": -0.3
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.0052314340953031335,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.5122523869103898,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.48096473193091765,
      "volat_points": 0,
      "day_range_pct": 0.012518577798102193,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 61.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 11,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 73.33,
        "contribution": 11
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 19.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 63.67,
        "contribution": 19.1
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 58.9,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 11/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 19.1/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 11.6,
      "市場環境": 11,
      "情緒分析": 4,
      "技術信號": 19.1,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 185.82415451,
          "volumePoints": 0.5,
          "revenuePoints": 0.6,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DXCM",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.21
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 719.7049948000001,
                "ma50": 711.88239742,
                "name": "QQQ",
                "close": 741.099976,
                "points": 2
              },
              "spy": {
                "ma20": 765.3379966,
                "ma50": 761.1531977799998,
                "name": "SPY",
                "close": 767.17999,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.723333714416371,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142370918,
                "url": "https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...",
                "category": "company",
                "datetime": 1790224168,
                "headline": "Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"
              },
              {
                "id": 142366064,
                "url": "https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...",
                "category": "company",
                "datetime": 1790201622,
                "headline": "DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"
              },
              {
                "id": 142025511,
                "url": "https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DXCM",
                "summary": "DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...",
                "category": "company",
                "datetime": 1788952625,
                "headline": "DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141953963,
                "url": "https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.",
                "category": "company",
                "datetime": 1788871017,
                "headline": "DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"
              },
              {
                "id": 141425987,
                "url": "https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...",
                "category": "company",
                "datetime": 1788506376,
                "headline": "DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"
              },
              {
                "id": 141403938,
                "url": "https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.",
                "category": "company",
                "datetime": 1788463638,
                "headline": "Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"
              },
              {
                "id": 141364461,
                "url": "https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788275900,
                "headline": "3 Reasons DXCM Has Explosive Upside Potential"
              },
              {
                "id": 141329259,
                "url": "https://finnhub.io/api/news?id=30fc1b6357c6f2bc8fc26f712b11c5d05fc571cd1fc2a9682680b6e7df422e18",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "DXCM",
                "summary": "Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.",
                "category": "company",
                "datetime": 1787829714,
                "headline": "DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation"
              }
            ],
            "raw_source": [
              {
                "id": 142370918,
                "url": "https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...",
                "category": "company",
                "datetime": 1790224168,
                "headline": "Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"
              },
              {
                "id": 142366064,
                "url": "https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...",
                "category": "company",
                "datetime": 1790201622,
                "headline": "DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"
              },
              {
                "id": 142364255,
                "url": "https://finnhub.io/api/news?id=895685be22cd87859303846feda7f64760fc0297ce940d33c824aa0414d154ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.",
                "category": "company",
                "datetime": 1790101500,
                "headline": "Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring"
              },
              {
                "id": 142310755,
                "url": "https://finnhub.io/api/news?id=92eed5103bf0ea374a58ca1e7b576333d065b92ab5af27bca906a641b348f8df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1789988065,
                "headline": "2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down"
              },
              {
                "id": 142307394,
                "url": "https://finnhub.io/api/news?id=7bc174f162091d9036397952184db2de41e5e61e125e11ffded05e0f7cc529bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- \"Wearable Biosensors Market - Global Forecast to 2036\" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch",
                "category": "company",
                "datetime": 1789981440,
                "headline": "Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players"
              },
              {
                "id": 142271637,
                "url": "https://finnhub.io/api/news?id=730ce01b8e45e7d0d0cea2dc2e8151ad596a5f7f5e6060130ea168cdd26aa9e1",
                "image": "",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "Truist Securities  analyst Richard Newitter   maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.",
                "category": "company",
                "datetime": 1789735782,
                "headline": "Truist Securities Maintains Buy on DexCom, Raises Price Target to $102"
              },
              {
                "id": 142271638,
                "url": "https://finnhub.io/api/news?id=6ee129161211c25318ac879637ad4a449a31809f2b9f29daed78db95040e7dfb",
                "image": "",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "TD Cowen  analyst Joshua Jennings   reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.",
                "category": "company",
                "datetime": 1789728853,
                "headline": "TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target"
              },
              {
                "id": 142253117,
                "url": "https://finnhub.io/api/news?id=e11028fe46d2f48c6ef48e72b060b54606b0ee35c8994be445e30b364af77ec5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1789727560,
                "headline": "2 Unpopular Stocks That Should Get More Attention and 1 We Question"
              },
              {
                "id": 142197315,
                "url": "https://finnhub.io/api/news?id=f9b690efa346ffbc94d60bb451c6e3888d4bef728ac1204db8a94505ecd775e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.",
                "category": "company",
                "datetime": 1789529598,
                "headline": "Dexcom gives CFO Jereme Sylvain expanded role"
              },
              {
                "id": 142141666,
                "url": "https://finnhub.io/api/news?id=e1cab6faa1b4651b320e6f31733d8419da2548b0a2da7354abd2eaf3d116e8db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer",
                "category": "company",
                "datetime": 1789417800,
                "headline": "Dexcom Promotes Jereme Sylvain to Chief Operating Officer"
              },
              {
                "id": 142141667,
                "url": "https://finnhub.io/api/news?id=c8407fc472f5b8188b750160e88317d29915f29a69289864ca15585955b9537b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.",
                "category": "company",
                "datetime": 1789411440,
                "headline": "Here's Why You Should Retain DexCom Stock in Your Portfolio for Now"
              },
              {
                "id": 142066269,
                "url": "https://finnhub.io/api/news?id=a9b86a2669b0dee4fa3b7a2d1d65e1fb21112612dcc3ec4f51125f9f2cd786c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.",
                "category": "company",
                "datetime": 1789071300,
                "headline": "Dexcom Appoints Glenn Boehnlein to Board of Directors"
              },
              {
                "id": 142061722,
                "url": "https://finnhub.io/api/news?id=1b09565d259ac9bfe618da32adb94625e41d949d1b28c9c53714134c2294b0d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.",
                "category": "company",
                "datetime": 1789053664,
                "headline": "3 Quality Compounders with Impressive Fundamentals"
              },
              {
                "id": 142025511,
                "url": "https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DXCM",
                "summary": "DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...",
                "category": "company",
                "datetime": 1788952625,
                "headline": "DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141953963,
                "url": "https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.",
                "category": "company",
                "datetime": 1788871017,
                "headline": "DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"
              },
              {
                "id": 141425987,
                "url": "https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...",
                "category": "company",
                "datetime": 1788506376,
                "headline": "DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"
              },
              {
                "id": 141403938,
                "url": "https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.",
                "category": "company",
                "datetime": 1788463638,
                "headline": "Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"
              },
              {
                "id": 141396046,
                "url": "https://finnhub.io/api/news?id=90fc089244dc8485ed1bae6ed814953047aba3ac1c4095ec57995ccba0e89f82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Reviewing prior stock picks is how investors turn experience into valuable feedback.  A recommendation is only a thesis until the market tests it.  Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.",
                "category": "company",
                "datetime": 1788414660,
                "headline": "Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services"
              },
              {
                "id": 141364461,
                "url": "https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788275900,
                "headline": "3 Reasons DXCM Has Explosive Upside Potential"
              },
              {
                "id": 141364462,
                "url": "https://finnhub.io/api/news?id=13c97255d370689eb9f90297a0211b08089b8745c33c05d2de88651317780fa0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.",
                "category": "company",
                "datetime": 1788269400,
                "headline": "Dexcom Announces Upcoming Conference Presentation"
              },
              {
                "id": 141364463,
                "url": "https://finnhub.io/api/news?id=c9b6fc6bffb3e3d7e0e29642779ed31313c55591b3bc61dab67540e17181933a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1788183001,
                "headline": "Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today"
              },
              {
                "id": 141352563,
                "url": "https://finnhub.io/api/news?id=62cc47117b3b9089b94543a3b43428caf46231c1d5d9006a1fe7d5275c3d64c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.",
                "category": "company",
                "datetime": 1788100202,
                "headline": "Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed."
              },
              {
                "id": 141361642,
                "url": "https://finnhub.io/api/news?id=2d68e10e6a7fe49f93f31c64a7e7e06caaf9f1daf2c0dc4f723072ce37ddb7f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.",
                "category": "company",
                "datetime": 1787861759,
                "headline": "The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?"
              },
              {
                "id": 141329259,
                "url": "https://finnhub.io/api/news?id=30fc1b6357c6f2bc8fc26f712b11c5d05fc571cd1fc2a9682680b6e7df422e18",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "DXCM",
                "summary": "Discover why DexCom (DXCM) fits the Affordable Growth screen, balancing strong earnings growth with reasonable valuation and solid financial health.",
                "category": "company",
                "datetime": 1787829714,
                "headline": "DexCom (NASDAQ:DXCM): An Affordable Growth Play With Strong Momentum and Fair Valuation"
              },
              {
                "id": 141361644,
                "url": "https://finnhub.io/api/news?id=ac13f57821e8edb85d717370a97036cf679147e1084cd7f872b6af7481c57b7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.",
                "category": "company",
                "datetime": 1787828940,
                "headline": "Dexcom, Abbott await Medicare coverage expansion for CGMs"
              },
              {
                "id": 141323906,
                "url": "https://finnhub.io/api/news?id=d51cae098bce93cf8ef7e16d66ce95996ebfd0ed923bffa3c37acb05dd0b23af",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Abbott-Laboratories.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "The FDA authorized Abbott&#39;s Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.",
                "category": "company",
                "datetime": 1787736992,
                "headline": "FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking"
              },
              {
                "id": 141364465,
                "url": "https://finnhub.io/api/news?id=51438755ae79e1fd4c7678dd81bbf96f6a8b8b900a62658aeb72f370bcfe0a48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.",
                "category": "company",
                "datetime": 1787671440,
                "headline": "Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?"
              },
              {
                "id": 141364468,
                "url": "https://finnhub.io/api/news?id=f5f23b1f38e5783222ccb643de6fbd02540422cf97dae9f0047cc2cd7a0d4460",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.",
                "category": "company",
                "datetime": 1787668380,
                "headline": "Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?"
              },
              {
                "id": 141364467,
                "url": "https://finnhub.io/api/news?id=4e934f90b7cbf82177951e0319e55111a0b294d452106cc79bb6226e88699eb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "We all knew it was coming. The expected valuation may surprise, though.",
                "category": "company",
                "datetime": 1787616344,
                "headline": "Oura is reportedly eyeing a September IPO that could value it at more than $16B"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 29,
            "discarded_article_count": 21
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.1,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 4339169.233333333,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 5003977.7,
              "avg_vol_20": 4147238.85,
              "avg_vol_30": 4339169.233333333,
              "range_pct_10": 0.09254601577683776,
              "range_pct_20": 0.1148965359551846,
              "range_pct_30": 0.11775465874013945,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.153211002133688,
              "dist_to_20d_high": 0.05273987437730133,
              "down_shrink_days": 3,
              "breakout_level_20d": 92.34,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7859223300970875
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.723333714416371,
              "turnoverUsdM": 185.82415451,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DXCM",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 82.7058,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.4,
            "take_profit_price": 91.8435,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.446667428832742,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 2.3821,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.72
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -8.95
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0927
    },
    "kdj": {
      "d": 67.89,
      "j": 72.19,
      "k": 69.32,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 64.53
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 75475444,
      "recentSlope": 2745934.4,
      "previousSlope": -1061630
    },
    "rsi": 43.36,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 83.2031,
      "position": "SAR喺價下",
      "distancePct": 4.88,
      "previousTrend": "上升"
    },
    "ma50": 84.959,
    "macd": {
      "macd": 0.6391259024485407,
      "trend": "中性偏多",
      "signal": 0.7491431994545833,
      "histogram": -0.11001729700604257
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 87.5867,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.52,
      "score": 2,
      "avgVolume": 4062331,
      "currentVolume": 2124433
    },
    "derived": {
      "ma20": 87.7105,
      "ma50": 84.959,
      "prevClose": 87.73,
      "avgVolume10": 4862441,
      "avgVolume20": 4062331,
      "changePercent": -0.3,
      "avgVolumeForScore": 4062331
    },
    "ma_cross": {
      "ma20": 87.7105,
      "ma50": 84.959,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 87.785,
      "prevMa50": 84.6642,
      "spreadPct": 3.24,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 82.9498,
      "upper": 92.4712,
      "position": "中間"
    },
    "rsi_short": 51.41,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.52
    }
  }
}

Raw metrics JSON

 
{
  "close": 87.47,
  "volume": 2124433,
  "changePercent": -0.3
}

Scores are derived from cached daily market data using the Solorank 110-point standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.